Serological Characteristics and Antimicrobial Susceptibility of Streptococcus pneumoniae Isolated from Children 0–5 Years of Age in Different Regions of Russia

Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(2):177-187

​ Kozlov R.S., Chagaryan A.N., Kozlova L.V., Muravyev A.A.
polysaccharide conjugated vaccines serotypes of S. pneumoniae acute otitis media pneumonia invasive diseases
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(2):177-187

Abstract

This article presents results of the study on serotypes distribution of clinical and colonized strains of S. pneumoniae circulated in different regions of Russian Federation in children attended day-care centers and orphanages, and in pediatric patients under 5 years old acute otitis media (AOM), pneumonia or invasive diseases (sepsis, meningitis, ext). During the investigation, we determined that serotypes 1, 3, 4, 5, 6 7, 9, 14, 18, 19 and 23 circulated in different regions of Russian Federation, which constituent in 7-, 10- and 13-valent polysaccharide conjugated vaccines. Vaccine coverage is 405⁄69,5%, 438⁄75,2% and 470⁄80,7% (CI = 6.3), respectively. The majority of penicillin-resistant strains of S. pneumoniae pneumococcal serotypes corresponded to vaccinal ones.

  • 1. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR Recomm Rep 2010 ;59(RR-11):1-18.
  • 2. Козлов Р.С. Пневмококки: уроки прошлого – взгляд в будущее. – МАКМАХ, 2010. – С. 25
  • 3. WHO Global Immunization Vision and Strategy, April 2005. Available at URL: www.who.int/vaccines/GIVS/english/Global_imm._data_EN.pdf
  • 4. Prymula R., Peeters P., Chrobok V., Kriz P., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both S.pneumoniae and non-typable H.influenzae: a randomized double-blind efficacy study. Lancet 2006; 367:740–48.
  • 5. A. Gurtman. Immunogenicity and safety of a 13– valent pneumococcal conjugate vaccine given with routine pediatricvaccinations in the United States. 7th International Symposium on Pneumococci and Pneumococcal Diseases. Abstract 217.
  • 6. Russel F. Pneumococcal nasopharyngeal carriage following a reduced dose 7–valent pneumococcal conjugate vaccine schedule in infancy and 23–valent pneumococcal polysaccharide vaccine booster. – 7th International Symposium on Pneumococci and Pneumococcal Diseases. Abstract 206.
  • 7. Nuorti J.P., Whitney C.G. Prevention of pneumococcal disease among infants and children – use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR Recomm Rep 2010; 59(RR-11):1-18.
  • 8. Hausdorff W.P., Bryant J., Paradiso P.R., Siber G.R. Which pneumococcal serogroups cause the most invasive diseases: implications for conjugate vaccine formulation and use. Clin Infect Dis 2000. 30;100-21.
  • 9. Sauver J., Marrs C.F., Foxman B., et al. Risk factors for otitis media and carriage of multiple strains of Haemophilus influenzae and Streptococcus pneumoniae. Emerg Infect Dis 2000; 6:622-30.
  • 10. Вишнякова Л.А., Фаустова М.Е., Сологуб Т.С. Некоторые вопросы эпидемиологии пневмококковых инфекций. Журн Микробиол 1988; (8):64-8.
  • 11. Катосова Л.К., Кешикбаева А.А., Батуро А.П. и др. Микробиология 1987; 1:29-36.
  • 12. Lee S., Lee K., Kang Y., Bae S. Prevalence of serotype and multidrug-resistance of Streptococcus pneumoniae respiratory tract isolates in 265 adults and 36 children in Korea, 2002-2005. Microb Drug Resist 2010; 16(2):135- 42.
  • 13. Coffey T., Derron S., Daniels M., et al. Мultiple antibioticresistant S.pneumoniae recovered from Spanish hospitals (1988-1994): novel major clones of serotypes 14,19 F, and 15F. Microbiology 1996; 142:2742-57.
  • 14. Rusen, I.D. Fraser-Roberts M.D. Nasopharyngeal pneumococcal colonization among Kenyan children: antibiotic resistance, strain types and associations with human immunodeficiency virus type 1 infection. Ped Infect Dis J 1997; 16:656-62
  • 15. Jansen W.T., Snippe H. Short-chain oligosaccharide protein conjugates as experimental pneumococcal vaccines. Indian J Med Res 2004; 119(Suppl):7-12.
  • 16. Reinter R.R., Kaufhold A., Kuhnemund O., Luttichen R. Serum antibody responses to vaccination with 23-valent pneumococcal vaccine in splenectomized patients. Int J Med Microbiol Virol Parasitol Infect Dis 1994; 281:481- 90.
  • 17. Катосова Л.К., Клинико-биологическая оценка пневмотропной флоры при острых и хронических бронхолегочных болезнях у детей: Автореф. дис. д-ра биол. наук. - М., 1990. - С. 48.
  • 18. Таточенко В.К., Катосова Л.К..Уланова М.А. и др. Периодические и географические различия серотипового спекра пневмококков у детей с респираторными заболеваниями и здоровых носителей. Журн Микробиол Эпидемиол Иммунобиол 1994; (3):3-10.
  • 19. Ongkasuwan J., Valdez T.A., Hulten K.G., et al. Pneumococcal mastoiditis in children and the evergence of multidrug-resistant serotype 19A isolates. Pediatrics 2008; 122:34-9.
  • 20. van Gils E.J., Veenhoven R.H., Hak E., et al. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA 2010; 304:1099-106.
  • 21. Reinert R.R. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect 2009; 15(Suppl 3):7-11.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared